COVID-19大流行与肠易激综合征——有关系吗?

Q3 Medicine
V. Akhmedov
{"title":"COVID-19大流行与肠易激综合征——有关系吗?","authors":"V. Akhmedov","doi":"10.22416/1382-4376-2022-32-2-85-92","DOIUrl":null,"url":null,"abstract":"The aim: to reflect the features of the course of irritable bowel syndrome during the COVID-19 pandemic.Key points. It has been noted that the COVID-19 may contribute to the formation of post-infectious functional gastrointestinal diseases, given that angiotensin-converting enzyme-2 (ACE-2) receptors, the site of binding of the SARS-CoV-2 virus to human cells, are also present in epithelial intestinal cells; virus was found in feces in about half of patients, gastrointestinal symptoms, including diarrhea occur in about one fifth of patients, fecal calprotectin, a marker of GI inflammation is elevated in patients with COVID-19, macroscopically as well as histologically, patients show signs of damage mucous membrane of the gastrointestinal tract, and also, as noted above, they have a dysbiosis of the intestinal microbiota.Conclusion. It was shown that during the pandemic, more than 90 % of the interviewed patients with IBS had an exacerbation of IBS with an increase in symptoms such as bloating and cramps, and 75 % of them said that the exacerbation of symptoms was reflected in the activity of patients in everyday life. These factors dictate the need for an integrated approach in the management of such a group of patients with the use of modern multi-target drugs that affect the pathogenetic factors in the formation of functional gastrointestinal diseases, one of which is the Kolofort drug due to the triple multi-target mechanism of action on the pathogenesis of functional gastrointestinal diseases. ","PeriodicalId":33798,"journal":{"name":"Rossiiskii zhurnal gastroenterologii gepatologii koloproktologii","volume":"57 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COVID-19 Pandemic and Irritable Bowel Syndrome — is there a Relationship?\",\"authors\":\"V. Akhmedov\",\"doi\":\"10.22416/1382-4376-2022-32-2-85-92\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The aim: to reflect the features of the course of irritable bowel syndrome during the COVID-19 pandemic.Key points. It has been noted that the COVID-19 may contribute to the formation of post-infectious functional gastrointestinal diseases, given that angiotensin-converting enzyme-2 (ACE-2) receptors, the site of binding of the SARS-CoV-2 virus to human cells, are also present in epithelial intestinal cells; virus was found in feces in about half of patients, gastrointestinal symptoms, including diarrhea occur in about one fifth of patients, fecal calprotectin, a marker of GI inflammation is elevated in patients with COVID-19, macroscopically as well as histologically, patients show signs of damage mucous membrane of the gastrointestinal tract, and also, as noted above, they have a dysbiosis of the intestinal microbiota.Conclusion. It was shown that during the pandemic, more than 90 % of the interviewed patients with IBS had an exacerbation of IBS with an increase in symptoms such as bloating and cramps, and 75 % of them said that the exacerbation of symptoms was reflected in the activity of patients in everyday life. These factors dictate the need for an integrated approach in the management of such a group of patients with the use of modern multi-target drugs that affect the pathogenetic factors in the formation of functional gastrointestinal diseases, one of which is the Kolofort drug due to the triple multi-target mechanism of action on the pathogenesis of functional gastrointestinal diseases. \",\"PeriodicalId\":33798,\"journal\":{\"name\":\"Rossiiskii zhurnal gastroenterologii gepatologii koloproktologii\",\"volume\":\"57 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rossiiskii zhurnal gastroenterologii gepatologii koloproktologii\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22416/1382-4376-2022-32-2-85-92\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rossiiskii zhurnal gastroenterologii gepatologii koloproktologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22416/1382-4376-2022-32-2-85-92","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的:反映COVID-19大流行期间肠易激综合征病程的特点。要点。鉴于血管紧张素转换酶-2 (ACE-2)受体(SARS-CoV-2病毒与人类细胞的结合位点)也存在于上皮肠细胞中,因此COVID-19可能有助于感染后功能性胃肠道疾病的形成;约一半的患者粪便中发现病毒,约五分之一的患者出现胃肠道症状,包括腹泻,粪便钙保护蛋白(胃肠道炎症标志物)在COVID-19患者中升高,宏观和组织学上,患者表现出胃肠道粘膜损伤的迹象,并且如上所述,他们有肠道菌群失调。研究表明,在大流行期间,超过90%的受访IBS患者出现IBS加重,出现腹胀、痉挛等症状增加,其中75%的患者表示症状加重反映在患者日常生活中的活动上。这些因素决定了在管理这类患者时需要采用综合的方法,使用影响功能性胃肠道疾病形成的致病因素的现代多靶点药物,其中之一是Kolofort药物,由于其三重多靶点作用机制对功能性胃肠道疾病的发病机制起作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
COVID-19 Pandemic and Irritable Bowel Syndrome — is there a Relationship?
The aim: to reflect the features of the course of irritable bowel syndrome during the COVID-19 pandemic.Key points. It has been noted that the COVID-19 may contribute to the formation of post-infectious functional gastrointestinal diseases, given that angiotensin-converting enzyme-2 (ACE-2) receptors, the site of binding of the SARS-CoV-2 virus to human cells, are also present in epithelial intestinal cells; virus was found in feces in about half of patients, gastrointestinal symptoms, including diarrhea occur in about one fifth of patients, fecal calprotectin, a marker of GI inflammation is elevated in patients with COVID-19, macroscopically as well as histologically, patients show signs of damage mucous membrane of the gastrointestinal tract, and also, as noted above, they have a dysbiosis of the intestinal microbiota.Conclusion. It was shown that during the pandemic, more than 90 % of the interviewed patients with IBS had an exacerbation of IBS with an increase in symptoms such as bloating and cramps, and 75 % of them said that the exacerbation of symptoms was reflected in the activity of patients in everyday life. These factors dictate the need for an integrated approach in the management of such a group of patients with the use of modern multi-target drugs that affect the pathogenetic factors in the formation of functional gastrointestinal diseases, one of which is the Kolofort drug due to the triple multi-target mechanism of action on the pathogenesis of functional gastrointestinal diseases. 
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
44
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信